updated 5/9/2006 3:19:51 PM ET 2006-05-09T19:19:51

Merck and Co. is spending nearly $500 million to buy two smaller research companies, the New Jersey-based drug giant announced Tuesday.

The acquisitions of Lebanon, N.H.-based GlycoFi Inc. and Santa Clara, Calif.-based Abmaxis Inc., are both expected to close by the end of June.

The purchase announcements come two weeks after Chief Executive Richard T. Clark promised shareholders big changes to a pharmaceutical giant wounded in litigation over heart problems caused by its pain medication, Vioxx.

Merck officials say the deals will make the company a bigger player in the growing field of biologic drugs, which are made from living organisms such as yeast.

GlycoFi, a privately held biotechnology company, will cost Merck $400 million in cash; the price tag for Abmaxis, a privately held biopharmaceutical firm, is $80 million.

Merck previously had deals with both firms to develop or improve drugs.

© 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.91%
$30K home equity loan FICO 5.20%
$75K home equity loan FICO 4.57%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.42%
13.40%
Cash Back Cards 17.92%
17.92%
Rewards Cards 17.13%
17.12%
Source: Bankrate.com